Suscribirse

Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma - 24/02/22

Doi : 10.1016/j.diii.2022.01.006 
Shamar Young a, , Tina Sanghvi b, Sandeep Sharma a, Cameron Richardson a, Nathan Rubin a, Masters Richards a, Donna D'Souza a, Siobhan Flanagan a, Jafar Golzarian a
a University of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA 
b Minneapolis VA Medical Center, Department of Radiology, MN, 55417, USA 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

A significant proportion of patients with hepatocellular carcinoma who achieve complete radiologic response following transarterial chemoembolization will have local recurrence.
Variables such as liver function prior to transarterial chemoembolization and cause of underlying cirrhosis may predict local recurrence rates following complete response.
This study suggests that transarterial chemoembolization should be considered palliative and emphasizes the importance of long term follow up by interventional radiologists after treatment.

El texto completo de este artículo está disponible en PDF.

Abstract

Purpose

The purpose of this study was to determine the local progression rate and identify factors that may predict local progression, in patients who achieve a complete response (CR) radiologically after undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Materials and methods

One-hundred-forty-seven patients, who achieved CR of 224 HCCs after TACE, were retrospectively reviewed. There were 109 men and 38 women with a mean age of 61.6 ± 6.8 (SD) years (range: 45.4–86.9 years). Logistic mixed-effects and Cox regression models were used to evaluate associations between clinical factors and local progression.

Results

A total of 75 patients (75/147; 51%) and 99 (99/224,44.2%) lesions showed local progression at a median of 289.5 days (Q1: 125, Q3: 452; range: 51–2245 days). Pre-treatment, international normalization ratio (INR) (1.17 ± 0.15 [SD] vs. 1.25 ± 0.16 [SD]; P <0.001), model for end-stage liver disease (9.4 ± 2.6 [SD] vs. 10.6 ± 3.2 [SD]; P = 0.010) and Child-Pugh score (6 ± 1 [SD] vs. 6.4 ± 1.3 [SD]; P = 0.012) were significantly lower while albumin serum level (3.4 ± 0.62 [SD] vs. 3.22 ± 0.52 [SD]; P = 0.033) was significantly greater in those who showed local progression as compared to those who did not. In terms of local-recurrence free survival, the number of TACE treatments (hazard ratio [HR]: 2.05 [95% CI: 1.57–2.67]; P<0.001), INR (HR: 0.13 [95% CI: 0.03–0.61]; P = 0.010) and type of TACE (P = 0.003) were significant. Patients with local progression on any tumor did not differ from those who did in terms of overall survival (P = 0.072), however, were less likely to be transplanted (20/75, 26.7%) than those who did not (33/72; 36.1%) (P = 0.016).

Conclusion

A significant number of patients who achieve CR of HCC after TACE have local progression. This emphasizes the importance of long-term follow up.

El texto completo de este artículo está disponible en PDF.

Keywords : End stage liver disease, Interventional radiology, Hepatocellular carcinoma, Survival studies, Therapeutic chemoembolization


Esquema


© 2022  Société française de radiologie. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 103 - N° 3

P. 143-149 - mars 2022 Regresar al número
Artículo precedente Artículo precedente
  • Structured and shared MRI staging lexicon and report of rectal cancer: A consensus proposal by the French Radiology Group (GRERCAR) and Surgical Group (GRECCAR) for rectal cancer
  • Stephanie Nougaret, Pascal Rousset, Kirsten Gormly, Oliver Lucidarme, Serge Brunelle, Laurent Milot, Cécile Salut, Franck Pilleul, Lionel Arrivé, Constance Hordonneau, Guillaume Baudin, Philippe Soyer, Vanessa Brun, Valérie Laurent, Celine Savoye-Collet, Iva Petkovska, Jean Pierre Gerard, Eric Rullier, Eddy Cotte, Philippe Rouanet, Regina G.H. Beets-Tan, Nora Frulio, Christine Hoeffel
| Artículo siguiente Artículo siguiente
  • External validation of a commercially available deep learning algorithm for fracture detection in children
  • Michel Dupuis, Léo Delbos, Raphael Veil, Catherine Adamsbaum

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.